Bumetanide, Na+/2Cl-/K+ cotransporter inhibitor

Be the first to review this product! Submit a review

|

(0 Publication)

MW 364.4 Da, Purity >98%. Potent, selective Na+/2Cl-/K+ cotransporter inhibitor. Shows 40-fold greater potency than furosemide (). Shows diuretic and anticonvulsant effects *in vivo.* Orally active.

View Alternative Names

CA 12, CA 14, CA 7, CA IV, CA VB, CA-IX, CA-VII, CA-XII, CA-XIV, CA4, CA5B, CA9, CAH12_HUMAN, CAH14_HUMAN, CAH4_HUMAN, CAH5B_HUMAN, CAH7_HUMAN, CAH9_HUMAN, Car4, Carbonate dehydratase IV, Carbonate dehydratase IX, Carbonate dehydratase VB, Carbonate dehydratase VII, Carbonate dehydratase XII, Carbonate dehydratase XIV, Carbonic anhydrase 12, Carbonic anhydrase 14, Carbonic anhydrase 4, Carbonic anhydrase 5B, Carbonic anhydrase 5B, mitochondrial, Carbonic anhydrase 7, Carbonic anhydrase 9, Carbonic anhydrase IX, Carbonic anhydrase VB, Carbonic anhydrase VB, mitochondrial, Carbonic anhydrase VII, Carbonic anhydrase XII, Carbonic anhydrase XIV, Carbonic dehydratase, Carbonic dehydratase IV, Carbonic dehydratase VII, EC 4.2.1.1, EC=4.2.1.1, FLJ20151, HsT18816, MN, Membrane antigen MN, P54/58N, RCC associated protein G250, RCC-associated antigen G250, RP17, Renal cell carcinoma-associated antigen G250, Retinitis pigmentosa 17 (autosomal dominant), T18816, Tumor antigen HOM-RCC-3.1.3, UNQ690/PRO1335, mitochondrial, pMW1